Meeting
2023 ASCO Breakthrough
Second chance for cure: Stereotactic ablative radiotherapy in oligometastatic disease.
Authors
Nidal Salim
European Medical Center, Moscow, Russian Federation
Nidal Salim , Kristina Tumanova , Alexey Popodko , Eugene Libson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Advanced Disease
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 154)
DOI
10.1200/GO.2023.9.Supplement_1.154
Abstract #
154
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.
First Author: Philip Sutera
Poster
2020 ASCO Virtual Scientific Program
Cost-effectiveness analysis of stereotactic ablative radiotherapy in patients with oligometastatic cancer.
First Author: Abhishek Kumar
Poster
2015 ASCO Annual Meeting
Stereotactic ablative radiotherapy (SABR) as re-irradiation for an isolated infield lymph node recurrence.
First Author: Neal E Dunlap
Poster
2024 ASCO Breakthrough
Systemic treatment post curative-intent intervention based on tumor-informed circulating tumor DNA result for oligometastatic colorectal cancer.
First Author: Teerada Siripoon